Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Millennium Withdraws Velcade Follicular Lymphoma sNDA, Citing Business Decision

This article was originally published in The Pink Sheet Daily

Executive Summary

The company will continue to evaluate bortezomib in follicular lymphoma subgroups as part of its larger development program for the first-in-class proteasome inhibitor.
Advertisement

Related Content

Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance
Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance
Onyx Files Carfilzomib For Accelerated Approval With Two Phase III Trials Ongoing
Onyx Files Carfilzomib For Accelerated Approval With Two Phase III Trials Ongoing

Topics

Advertisement
UsernamePublicRestriction

Register

PS072981

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel